Assertio (ASRT) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1 year target prices for Assertio's stock. Their ASRT share price forecasts range from $9.00 to $10.00. On average, they anticipate the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts.

Assertio's stock was trading at $4.30 at the beginning of the year. Since then, ASRT shares have increased by 50.2% and is now trading at $6.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ASRT earnings forecast.

Assertio Holdings, Inc. (NASDAQ:ASRT) released its earnings results on Wednesday, March, 8th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $0.23 by $1.11. The company had revenue of $50.35 million for the quarter, compared to analyst estimates of $49.57 million. Assertio had a trailing twelve-month return on equity of 52.50% and a net margin of 59.86%.

ETFs with the largest weight of Assertio (NASDAQ:ASRT) stock in their portfolio include Hartford Multifactor Small Cap ETF (ROSC).Barrons 400 ETF (BFOR).

Assertio updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$38.00 million, compared to the consensus revenue estimate of $37.59 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

Assertio trades on the NASDAQ under the ticker symbol "ASRT."

Assertio's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.62%), Acadian Asset Management LLC (2.07%), BlackRock Inc. (1.73%), American Century Companies Inc. (1.16%), Two Sigma Investments LP (1.16%) and Arrowstreet Capital Limited Partnership (1.07%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Group LP Cr, Heather L Mason, James L Tyree and Paul Schwichtenberg.
View institutional ownership trends.

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASRT stock can currently be purchased for approximately $6.46.

Assertio (NASDAQ:ASRT) has a market capitalization of $359.82 million and generates $156.23 million in revenue each year. The company earns $109.63 million in net income (profit) each year or $1.51 on an earnings per share basis.

Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The official website for the company is www.assertiotx.com. The company can be reached via phone at (224) 419-7106, via email at investor@assertiotx.com, or via fax at 510-744-8001.